On 9 April, during the Late-Breaking Science Session at the 2025 American Academy of Neurology (AAN) meeting, Remegen announced exciting results from a Phase III clinical trial evaluating the efficacy ...

The report found more than 1,000 hate incidents over the past five years. Twenty-six Illinois counties had at least six hate incidents each, including Coles, Macon, McLean and Rock Island counties.

Hate leafleting has become an increasingly common means for extremist groups to espouse hateful messages and intimidate ...

The report found more than 1,000 hate incidents over the past five years. Twenty-six Illinois counties had at least six hate ...

Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with generalized myasthenia gravis, a phase 3 trial suggests.

Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized myasthenia gravis ...

ILLINOIS ( 25News Now) - A new report from the Anti-Defamation League says that hate and extremism incidents are up ...

ADL and Hillel must stop undermining the president’s actions, and the Jewish community should be thanking Trump.

The randomized control period of the MINT trial has completed, and these newest data describe outcomes among patients who ...

Johnson & Johnson reports long-term efficacy and steroid-sparing benefits of nipocalimab in antibody-positive generalized ...

Cartesian reports 12-month data for Descartes-08 in myasthenia gravis; Phase 3 AURORA trial expected to begin in Q2 2025.